Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)

Arndt Vogel; Shukui Qin; Masatoshi Kudo; Stacie Hudgens; Tatsuya Yamashita; Je‐Hyun Yoon; Lætitia Fartoux; Krzysztof Simon; Carlos López; Max W. Sung; Corina E. Dutcus; Silvija Kraljevic; Toshiyuki Tamai; Nathan Grunow; Genevieve Meier; В. В. Бредер

doi:10.1093/annonc/mdx369.002

Article2017

Health-Related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)

Arndt Vogel, Shukui Qin, Masatoshi Kudo, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Mike Sung, Corina E. Dutcus, Silvija Kraljevic, Toshiyuki Tamai, Nathan Grunow, Genevieve Meier, В. В. Бредер

Article2024

ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.

T.R. Jeffry Evans, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean-Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Shukui Qin, Taisuke Hoshi, Ryuji Tamaki, Yasuhiro Funahashi, Chinyere E. Okpara, Koji Sagane, Dongyuan Xing, Yukinori Minoshima, Richard S. Finn

Article2017

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Ann‐Lii Cheng, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean–Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Min Ren, Silvija Kraljevic, Toshiyuki Tamai, Masatoshi Kudo

Article2018

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Rkc Ngan, J.-F. Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang–Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Yasuhiro Funahashi, T.R. Jeffry Evans

Article2025

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.

Masatoshi Kudo, Thomas Yau, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Nan Hu, Maria Jesus Jimenez Exposito, Caitlyn Stromko, Peter R. Galle

Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)

Discussion(0)

Related publications

Health-Related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)

ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.